Publications by authors named "Kremena Petrova Trichkova"
Cancers (Basel)
January 2024
Article Synopsis
- Malignant melanoma is a rising and aggressive form of cancer, and while immune checkpoint inhibitors (ICIs) have improved survival rates for patients with advanced cases, they can also lead to severe immune-related adverse events (irAEs).
- This systematic review examined whether specific patient characteristics could help predict the likelihood of developing severe gastrointestinal, liver, and lung irAEs when treated with ipilimumab and/or nivolumab/pembrolizumab.
- The analysis found no significant links between patient factors like age, gender, or overall health status and the risk of severe irAEs across different treatment options, highlighting a need for better reporting standards in future studies.
